Cure Pharmaceutical, an Oxnard-based public company working on drug delivery systems and cannabis therapies, said July 28 that it has agreed to acquire Sera Labs, a privately owned CBD company, in a 95-percent stock deal that includes $19 million in stock at $2.75 per share. Cure, which shares are traded over the counter, closed unchanged at…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
